BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.

BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...

BridgeBio Pharma (BBIO) stock jumps as a Phase 3 trial for the company's achondroplasia therapy succeeds. Read more here.

Feb 12 (Reuters) - BridgeBio Pharma said its experimental therapy boosted growth rates in children with a rare genetic ...

A: Little People of America defines it as a "medical or genetic condition that usually results in an adult height of 4 feet 10 inches or shorter." There are several types of dwarfism. Q: What are most ...

BridgeBio Pharma Inc. BBIO stock is surging on Thursday and nearing the upper end of its 52-week range of $28.33-$84.94, ...

Shares in BridgeBio were ticking up today after it revealed data from its phase 3 trial of infigratinib in achondroplasia, ...

Add Yahoo as a preferred source to see more of our stories on Google. October is a month of recognition for many in Erie and beyond. For 65,000 people in the nation born with dwarfism, the month ...

Feb 12 (Reuters) - BridgeBio Pharma said on Thursday its experimental therapy boosted growth rates in children with a rare ...